Ortho-McNeil Regranex
Executive Summary
Enrollment halted in Phase III study designed to evaluate the efficacy of becaplemin gel .01% in the treatment of pressure ulcers. The company said they will no longer disseminate reprints of Phase II trial findings, published in the May-June issue of Wound Repair and Regeneration, and have notified healthcare professionals who previously received reprints that "no final conclusion can be drawn" from the inconsistent findings